HEALWELL More than Doubles YoY Adjusted EBITDA in Q3-2026 and Improves YTD Operating Cashflow by $26 Million

Nine-month operating cash flow improved by C$26.0 million, while quarterly gross margin declined and continuing operations remained loss-making.

Rhea-AI Summary

HEALWELL AI (HWAIF) reported third-quarter 2026 revenue from continuing operations of C$32.6 million, up 7% year over year. Adjusted EBITDA, a non-standardized profitability measure, rose 144% to C$1.6 million. The continuing-operations net loss remained approximately C$16.0 million, while gross margin fell to 52% from 54%.

Nine-month operating cash flow turned positive at C$5.9 million, versus C$20.1 million used a year earlier. September-end cash was C$14.9 million, down from C$18.6 million at December-end. Healthcare Software revenue grew 9% in the quarter; Data Science & AI revenue fell to C$1.5 million from C$2.0 million. Orion Health signed a multi-million-dollar, multi-year agreement with Converge Health Iowa, expected to generate recurring revenue. HEALWELL's indirect SpaceX interest was valued at C$17.7 million, with lock-up restrictions expected to fully expire in February 2027.

19 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 14 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointQ3 continuing-operations revenue rose 7% to C$32.582 million; nine-month revenue increased 38% to C$98.746 million.
• Moderate pointQ3 adjusted EBITDA rose 144% to C$1.646 million; nine-month adjusted EBITDA increased 294% to C$3.518 million.
• Moderate pointNine-month operating cash flow reached C$5.9 million, versus C$20.1 million used a year earlier.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Converge Health Iowa signed a multi-million-dollar, multi-year agreement with Orion Health, expected to generate recurring revenue.
• Moderate pointQ3 operating loss narrowed 27% to C$6.275 million; nine-month operating loss narrowed 30% to C$18.267 million.
• Moderate pointQ3 total net loss narrowed 43% to C$15.900 million; nine-month net loss narrowed 65% to C$16.350 million.
• Moderate pointNine-month EBITDA turned positive at C$7.866 million, versus negative C$13.353 million a year earlier.
• Moderate pointIndirect SpaceX interest reached C$17.7 million at September-end, versus approximately C$4.6 million carrying value at March-end.
• Moderate point. Forward-looking: it has not happened yet and may not happen.SpaceX investment realization is expected within twelve months through a distribution intended to strengthen liquidity.

10 minor points

• Minor pointQ3 gross profit increased 3% to C$17.066 million; nine-month gross profit rose 37% to C$54.491 million.
• Minor pointQ3 operating expenses fell 7% to C$23.341 million year over year.
• Minor pointNine-month continuing-operations net loss narrowed 49% to C$16.489 million year over year.
• Minor pointQ3 Healthcare Software revenue grew 9% to C$31.038 million; nine-month revenue rose 44% to C$92.624 million.
• Minor pointQ3 subscription, support and maintenance revenue rose 9% to C$22.837 million; nine-month revenue grew 45% to C$66.239 million.
• Minor pointQ3 Healthcare Software professional-services revenue rose 8% to C$8.551 million; nine-month revenue grew 40% to C$27.125 million.
• Minor pointQ3 financing expenses declined 15% to C$3.217 million year over year.
• Minor pointQ3 foreign-exchange expense fell 99% to C$12,000; nine-month foreign exchange produced a C$43,000 gain.
• Minor pointNine-month fair-value changes in contingent consideration, investments and options produced a C$11.985 million gain, versus C$2.757 million expense.
• Minor pointCredit facilities remained in compliance with all covenants during the first nine months of 2026.

Negative

• Moderate pointQ3 continuing-operations net loss was C$16.039 million, versus C$15.998 million a year earlier.
• Moderate pointQ3 gross margin declined to 52% from 54% a year earlier.
• Moderate pointSeptember-end cash fell to C$14.9 million, from C$18.6 million at December 31, 2025.
• Moderate pointNine-month operating expenses increased 11% to C$72.758 million year over year.
• Moderate pointQ3 cost of sales rose 12% to C$15.516 million; nine-month cost increased 39% to C$44.255 million.
• Moderate pointQ3 EBITDA deteriorated to negative C$7.384 million, from negative C$6.366 million a year earlier.

8 minor points

• Minor pointQ3 Data Science & AI revenue fell to C$1.5 million from C$2.0 million, reflecting lower project-based life-sciences revenue.
• Minor pointQ3 fair-value expense for contingent consideration, investments and options rose 352% to C$5.048 million.
• Minor pointNine-month financing expenses increased 39% to C$9.376 million year over year.
• Minor pointQ3 derivative-liability fair-value expense rose 26% to C$614,000; nine-month gain fell to C$1.065 million from C$2.838 million.
• Minor pointQ3 tax expense rose to C$873,000 from C$106,000; nine-month expense replaced a prior-year tax benefit.
• Minor pointQ3 Healthcare Software license revenue fell 14% to C$108,000; nine-month revenue declined 32% to C$709,000.
• Minor pointQ3 Data Science & AI subscription revenue fell 33% to C$458,000, from C$684,000 a year earlier.
• Minor point. Forward-looking: it has not happened yet and may not happen.SpaceX investment remains subject to lock-up restrictions, expected to fully expire in February 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• HEALWELL achieved revenue from continuing operations of $32.6 million in Q3-2026, an increase of 7% compared to revenue of $30.4 million in Q3-2025.

• HEALWELL reported positive Adjusted EBITDA¹ of $1.6 million in Q3-2026, an increase of 144% compared to Adjusted EBITDA of $0.7 million in Q3-2025. The improvement in Adjusted EBITDA margin reflects improved performance across HEALWELL's operating segments and a 7% reduction in total operating expenses. Net loss from continuing operations, was $16.0 million in Q3-2026, unchanged from $16.0 million in Q3-2025.

• Cash flow generated from operating activities was $5.9 million for the nine months ended September 30, 2026, compared to cash used of $20.1 million in the prior-year period, representing an improvement of $26.0 million, reflecting operating efficiencies realized across the organization.

• On September 1, HEALWELL announced its subsidiary, Orion Health, had entered into a multi-million-dollar, multi-year agreement with Converge Health Iowa to deploy DARWEN™-powered SMART Search and SMART Summary across Iowa's statewide Health Information Exchange, an existing Orion Health customer relationship.

Toronto, Ontario--(Newsfile Corp. - November 9, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce its unaudited interim condensed consolidated financial results for the quarter and nine months ended September 30, 2026. A summary of the Company's financial and operational results is set out below, and more detailed information is contained in the interim financial statements and related management discussion and analysis, which are available on the Company's SEDAR+ page at www.sedarplus.ca. Financial measures described as "Adjusted" or "EBITDA" in this news release are non-IFRS financial measures and may not be comparable to other similar measures disclosed by other companies. Please see Non-IFRS Financial Measures below for more information.

James Lee, Chief Executive Officer of HEALWELL, commented, "The third quarter demonstrated the commercial model we have been building since the Orion Health acquisition. Our agreement with Converge Health Iowa expands an existing Orion Health infrastructure relationship into DARWEN™-powered AI across a statewide health information exchange, and the deployment of SMART Summary across New Brunswick through Intrahealth brings our AI directly into the clinical workflows of front-line providers. Together with the growth of the WELLTRUST™ consented patient network and the continued peer-reviewed validation of DARWEN™, these milestones reflect our strategy of embedding clinically validated AI across our software carriage network. We remain focused on replicating these cross-sell opportunities across our global customer base as we continue to grow our recurring revenue."

Anthony Lam, Chief Financial Officer of HEALWELL, commented, "Our third quarter results reflect the progress we are making in driving operational efficiencies, improving margins, and transitioning toward larger, recurring enterprise opportunities. During the first nine months of 2026, we generated $5.9 million in cash flow from operating activities, representing a $26.0 million improvement over the prior-year period, while remaining in compliance with all covenants under our credit facilities. With $14.9 million in cash and cash equivalents and a $17.7 million short-term investment representing our indirect interest in SpaceX, we believe we are well-positioned to maintain financial flexibility as we continue to focus on disciplined capital allocation and achieving sustained profitability."

Third Quarter 2026 Financial Highlights

Significant financial highlights for the Company's continuing operations during the three months ended September 30, 2026 included:

• HEALWELL achieved quarterly revenue from continuing operations of $32.6 million in Q3-2026, an increase of 7% compared to revenue of $30.4 million generated in Q3-2025.

• HEALWELL achieved Gross Profit of $17.1 million during Q3-2026, an increase of 3% compared to $16.5 million in Q3-2025.

• HEALWELL achieved a Gross Margin percentage of 52% during Q3-2026, compared to 54% in Q3-2025.

• During Q3-2026, HEALWELL reported positive Adjusted EBITDA¹ of $1.6 millionin Q3-2026, an increase of 144% compared to Adjusted EBITDA of $0.7 million in Q3-2025.

• During Q3-2026, the Company's IFRS net loss from continuing operations was $16.0 million, compared to a net loss of $16.0 million for the previous year, as a $2.3 million improvement in loss from operations was offset primarily by higher non-cash charges for changes in the fair value of contingent consideration, investments and options.

• As of September 30, 2026, HEALWELL had $14.9 million in cash, compared to $18.6 million as of December 31, 2025.

• Data Science & AI segment revenue was $1.5 million in Q3-2026 compared to $2.0 million in Q3-2025, reflecting lower project-based life sciences revenue. During 2026, HEALWELL has focused on productizing its DARWEN™ AI capabilities for delivery through its Healthcare Software platforms, including the Converge Health Iowa and New Brunswick deployments, with the resulting recurring revenue reported within the Healthcare Software segment, where Subscription, Support and Maintenance revenue grew 10% compared to Q3-2025.

Third Quarter 2026 Business and Operational Highlights

Significant business and operational highlights for the Company during the three months ended September 30, 2026 included:

• International Prix Galien Nomination: On August 19, 2026, HEALWELL announced that its subsidiary Pentavere Research Group (now HEALWELL DARWEN Inc.), developer of DARWEN™ AI, had been nominated for the 2026 International Prix Galien Award in the Best Startup category, following its receipt of the 2024 Prix Galien USA Award for Best Digital Health Startup. The International Prix Galien is held every two years and brings together innovations that have already earned Prix Galien recognition in national and regional competitions around the world.

• Statewide U.S. HIE AI Deployment: On September 1, 2026, HEALWELL, through its subsidiary Orion Health, announced an agreement with Converge Health Iowa, Iowa's designated statewide Health Information Exchange ("HIE") and an existing Orion Health customer, to deploy DARWEN™-powered SMART Search and SMART Summary across Iowa's statewide HIE infrastructure, which currently receives data from 115 hospitals. The multi-million-dollar, multi-year agreement is expected to generate recurring revenue over its term and reflects HEALWELL's strategy of cross-selling its AI capabilities across Orion Health's global enterprise customer base.

• WELLTRUST™ Clinical Trial Matching: On September 8, 2026, HEALWELL and WELL Health Technologies Corp. announced that WELLTRUST™, a WELL-managed network of consented patients that uses HEALWELL's DARWEN™ AI to match clinical trial protocols against the consented patient population, had surpassed 100,000 patient consents since its launch in February 2026.

• Benchmark Performance: On September 15, 2026, HEALWELL announced new peer-reviewed research in which DARWEN™-powered SMART Suite clinical summaries outperformed published benchmarks for OpenAI's GPT, DeepSeek and Llama, with average improvements of up to 43%, and DARWEN™ delivered nearly 50% higher treatment-plan accuracy than a leading general-purpose AI model in blinded clinician review. A study published in the Canadian Journal of Cardiology also found that SMART Patient ID identified more than 4,100 heart failure patients not receiving guideline-directed medical therapy.

• SMART Summary Deployment in New Brunswick: On September 23, 2026, HEALWELL announced the deployment of DARWEN™-powered SMART Summary to customers across New Brunswick through its subsidiary Intrahealth, making the solution available to more than 400 clinicians. The deployment follows the evaluation of SMART Summary through Canada Health Infoway's Vendor Innovation Program.

• SpaceX Investment: As of September 30, 2026, the fair value of the Company's indirect interest in SpaceX was $17.7 million, based on their market price and exchange rates in effect on that date, as compared to a carrying value of approximately CAD$4.6 million reflected in the Company's financial statements as of March 31, 2026. HEALWELL acquired its indirect interest in SpaceX through its prior investment in xAI Corp. in May 2024, which was acquired by SpaceX in February 2026. The investment continues to be held indirectly through a private fund and is subject to customary lock-up restrictions which are expected to fully expire in February 2027. Management expects to realize the investment within twelve months through a distribution, with the proceeds intended to strengthen HEALWELL's balance sheet and liquidity position.

Events Subsequent to September 30, 2026

Significant business and operational highlights for the Company subsequent to September 30, 2026 included:

• Peer-Reviewed MyHealthNB Research and DARWEN™ Governance Recognition: On October 6, 2026, HEALWELL announced that peer-reviewed research published in the Journal of Medical Internet Research found that MyHealthNB, New Brunswick's provincial personal health record built on VeroSource technology, was associated with statistically significant, self-reported improvements in patient empowerment and healthcare engagement.

• TIME Recognition and Fall Research Program: On October 15, 2026, HEALWELL announced that it had been named to TIME's World's Top HealthTech Companies of 2026 in the AI & Data Analytics category, and that HEALWELL and its collaborators are presenting 12 scientific abstracts and presentations at 8 international conferences this fall.

Webcast and Conference Call Details

HEALWELL will be holding a conference call and simultaneous webcast to discuss its financial results on Tuesday, November 10, 2026 at 8:30 am EST (6:30 am PCT). The call will be hosted by James Lee, Chief Executive Officer, Dr. Alexander Dobranowski, President, and Anthony Lam, Chief Financial Officer. Please dial-in 10 minutes prior to the start of the call.

Date: Tuesday, November 10, 2026
Time: 8:30 AM EST / 6:30 AM PCT
Webcast link: https://bit.ly/AIDX-Q3
Toll-Free North America: (+1) 800 431 2204
Toronto Local and International Toll: (+1) 289 514 5015

When connecting to the conference call via phone, please dial in 10 minutes prior to the start of the call and ask to be joined into the "HEALWELL AI Inc. Conference Call."

Selected Financial Information

(in thousands of Canadian dollars, except percentages and per share amounts)

	Three months ended						Period-Over-Period Change						Nine months ended						Period-Over-Period Change
		September 30,												September 30,
		2026			2025			$			%			2026			2025			$			%
Revenue		32,582			30,354			2,228			7%			98,746			71,587			27,159			38%
Cost of Sales		15,516			13,844			1,672			12%			44,255			31,940			12,315			39%
Gross Profit		17,066			16,510			556			3%			54,491			39,647			14,844			37%
Operating Expenses
General and administrative		7,745			8,187			(442	)		(5)%			25,958			23,049			2,909			13%
Research and development		4,557			4,892			(335	)		(7)%			15,440			12,121			3,319			27%
Sales and marketing		2,820			2,386			434			18%			8,949			5,822			3,127			54%
Share-based payments		2,950			3,148			(198	)		(6)%			7,040			10,169			(3,129	)		(31)%
Amortization of intangible assets		4,474			5,565			(1,091	)		(20)%			12,946			12,863			83			1%
Depreciation of property and equipment		157			192			(35	)		(18)%			326			465			(139	)		(30)%
Depreciation of ROU assets		638			732			(94	)		(13)%			2,099			1,276			823			64%
Total Operating Expenses		23,341			25,102			(1,761	)		(7)%			72,758			65,765			6,993			11%
Loss from Operations		(6,275	)		(8,592	)		2,317			27%			(18,267	)		(26,118	)		7,851			30%
Other Income and Expenses
Financing expenses		3,217			3,769			(552	)		(15)%			9,376			6,750			2,626			39%
Effect of foreign exchange rate		12			1,927			(1,915	)		(99)%			(43	)		644			(687	)		(107)%
Changes in FMV of Contingent Consideration, Investments and Options		5,048			1,116			3,932			352%			(11,985	)		2,757			(14,742	)		(535)%
Changes in FV of derivative liability		614			488			126			26%			(1,065	)		(2,838	)		1,773			62%
Current and Deferred Taxes		873			106			767			724%			1,939			(1,062	)		3,001			283%
Net loss from continuing operations		(16,039	)		(15,998	)		(41	)		-%			(16,489	)		(32,369	)		15,880			49%
Net loss from discontinued operations		139			(12,011	)		12,150			101%			139			(13,803	)		13,942			101%
Net loss for the period		(15,900	)		(28,009	)		12,109			43%			(16,350	)		(46,172	)		29,822			65%
EBITDA[1][2]		(7,384	)		(6,366	)		(1,018	)		(16)%			7,866			(13,353	)		21,219			159%
ADJUSTED EBITDA1		1,646			675			971			144%			3,518			892			2,626			294%
Subscription, Support and Maintenance Revenue		22,837			21,014			1,823			9%			66,239			45,699			20,540			45%

 

^[1] EBITDA and Adjusted EBITDA are non-IFRS financial measures and do not have any standardized meaning under IFRS Accounting Standards. These measures may not be comparable to similar measures used by other issuers. See "Non-IFRS Measures".

^[2] EBITDA and Adjusted EBITDA are non-IFRS financial measures and do not have any standardized meaning under IFRS Accounting Standards. These measures may not be comparable to similar measures used by other issuers. See "Non-IFRS Measures".

Segmented Revenue

Healthcare Software	Three months ended September 30,						Period-Over-Period Change							Nine months ended September 30,					Period-Over-Period Change
		2026			2025			$			%			2026			2025			$			%
Subscription, Support and Maintenance		22,379			20,330			2,049			10%			64,790			44,093			20,697			47%
Professional Services		8,551			7,925			626			8%			27,125			19,402			7,723			40%
Software License		108			126			(18	)		(14)%			709			1,037			(328	)		(32)%
Total Revenue		31,038			28,381			2,657			9%			92,624			64,532			28,092			44%

 

Data Science & AI	Three months ended September 30,						Period-Over-Period Change							Nine months ended September 30,						Period-Over-Period Change
		2026			2025			$			%			2026			2025			$			%
Subscription, Support and Maintenance		458			684			(226	)		(33)%			1,449			1,606			(157	)		(10)%
Professional Services		1,086			1,289			(203	)		(16)%			4,673			5,449			(776	)		(14)%
Software License		-			-			-			0%			-			-			-			0%
Total Revenue		1,544			1,973			(429	)		(22)%			6,122			7,055			(933	)		(13)%

 

Non-IFRS Financial Measures

The terms EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin used in this document do not have any standardized meaning under IFRS, may not be comparable to similar financial measures disclosed by other companies and should not be considered a substitute for, or superior to, IFRS financial measures. Readers are advised to review the section entitled "Non-IFRS Financial Measures" in the Company's management discussion and analysis for the quarter ended September 30, 2026, available on the Company's SEDAR+ page at www.sedarplus.ca, for a detailed explanation of the composition of these measures and their uses.

The following table reconciles EBITDA and Adjusted EBITDA to net loss from continuing operations for the three and nine months ended September 30, 2026 and September 30, 2025:

		Three months ended						Nine months ended
	September 30,			September 30,			September 30,			September 30,
		2026			2025			2026			2025
Net loss		(16,039	)		(15,998	)		(16,489	)		(32,369	)
Add: Financing expenses		3,217			3,769			9,376			6,750
Add: Depreciation of property equipment		157			192			326			465
Add: Amortization of intangible assets		4,474			5,565			12,946			12,863
Less: Lease interest and bank charges retained in EBITDA		(66	)		-			(232	)		-
Add: Current and deferred taxes		873			106			1,939			(1,062	)
EBITDA		(7,384	)		(6,366	)		7,866			(13,353	)
Add: Restructuring and Integration cost		109			54			1,042			532
Add: Effect of foreign exchange rate		12			1,927			(43	)		644
Add: Changes in FMV of Contingent Consideration, Investments Options		5,048			1,116			(11,985	)		2,757
Add: Stock compensation		2,950			3,148			7,040			10,169
Add: Acquisition related expenses		297			308			663			2,981
Less: Changes in FV of derivative liability		614			488			(1,065	)		(2,838	)
Adjusted EBITDA		1,646			675			3,518			892

 

¹ EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin are non-IFRS financial measures. See "Non-IFRS Financial Measures" above.

James Lee
Chief Executive Officer
HEALWELL AI Inc.

About HEALWELL AI

HEALWELL AI is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve health outcomes with better care and technology. HEALWELL is executing its strategy by developing and acquiring technology and clinical science capabilities that complement its business of preventative care, including data science, AI-powered patient identification, and clinical decision support. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". Learn more at www.healwell.ai.

Forward-Looking Statements

Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including statements about the expected benefits of, and recurring revenue to be generated over the term of, the Company's agreement with Converge Health Iowa; the Company's ability to cross-sell its AI solutions across Orion Health's customer base; the expected expiry of lock-up restrictions on the Company's indirect interest in SpaceX common shares and the future value of that investment; the continued deployment of the Company's SMART Suite and the continued growth of the WELLTRUST™ consented patient network; the Company's ability to continue generating positive cash flow from operating activities; and the Company's strengthening financial foundation; and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as "growing", "strengthening", "enabling", "accelerating", "building", "transitioning", "improving", "trends", "becoming", "maintaining", "planned", "expects", "continues to", "expanding", "strategy", "believes", "intended" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms. Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: HEALWELL's ability to leverage Orion Health personnel, products, services, customers and relationships; HEALWELL's ability to maintain and leverage its relationships with its commercial partners; the successful implementation and customer acceptance of the Company's AI solutions; the continued adoption of the software, tools and solutions created by HEALWELL; that HEALWELL will be successful in identifying, executing and integrating new acquisitions, investments and/or partnerships; the market price of SpaceX common shares and the timing and terms of the release of lock-up restrictions and any distribution of the applicable securities; the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.

Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated March 18, 2026, which is available under HEALWELL's SEDAR+ profile at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.

For more information:

Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323259

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did HEALWELL AI's adjusted EBITDA perform in Q3 2026?

HEALWELL's adjusted EBITDA increased 144% to C$1.646 million, from C$675,000 in Q3 2025. Adjusted EBITDA is a non-IFRS measure without a standardized meaning and may not be comparable with similarly named measures from other companies.

What drove HEALWELL AI's operating cash flow improvement in 2026?

HEALWELL attributed its C$26.0 million improvement in nine-month operating cash flow to operating efficiencies across the organization. Operating activities generated C$5.9 million, compared with C$20.1 million used in the prior-year period.

How does HEALWELL AI hold its SpaceX investment?

HEALWELL holds its indirect SpaceX interest through a private fund. The interest originated from its investment in xAI in May 2024; SpaceX acquired xAI in February 2026.